Correlation Between Pharvaris and Immunic
Can any of the company-specific risk be diversified away by investing in both Pharvaris and Immunic at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pharvaris and Immunic into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pharvaris BV and Immunic, you can compare the effects of market volatilities on Pharvaris and Immunic and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pharvaris with a short position of Immunic. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pharvaris and Immunic.
Diversification Opportunities for Pharvaris and Immunic
Very good diversification
The 3 months correlation between Pharvaris and Immunic is -0.47. Overlapping area represents the amount of risk that can be diversified away by holding Pharvaris BV and Immunic in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immunic and Pharvaris is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pharvaris BV are associated (or correlated) with Immunic. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immunic has no effect on the direction of Pharvaris i.e., Pharvaris and Immunic go up and down completely randomly.
Pair Corralation between Pharvaris and Immunic
Given the investment horizon of 90 days Pharvaris BV is expected to generate 0.99 times more return on investment than Immunic. However, Pharvaris BV is 1.01 times less risky than Immunic. It trades about 0.06 of its potential returns per unit of risk. Immunic is currently generating about 0.02 per unit of risk. If you would invest 1,771 in Pharvaris BV on September 1, 2024 and sell it today you would earn a total of 419.00 from holding Pharvaris BV or generate 23.66% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Pharvaris BV vs. Immunic
Performance |
| Timeline |
| Pharvaris BV |
| Immunic |
Pharvaris and Immunic Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Pharvaris and Immunic
The main advantage of trading using opposite Pharvaris and Immunic positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pharvaris position performs unexpectedly, Immunic can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunic will offset losses from the drop in Immunic's long position.| Pharvaris vs. Pmv Pharmaceuticals | Pharvaris vs. Eliem Therapeutics | Pharvaris vs. MediciNova | Pharvaris vs. PepGen |
| Immunic vs. Generation Bio Co | Immunic vs. Kronos Bio | Immunic vs. Erasca Inc | Immunic vs. C4 Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Complementary Tools
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |